Literature DB >> 16552251

Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature.

Relief Jones1, Douglas J Rhee.   

Abstract

PURPOSE OF REVIEW: The purpose of this article is to briefly review the literature of corticosteroid-induced ocular hypertension and glaucoma, its risk factors, the pathophysiology, and treatment options. In particular, literature pertaining to glaucoma in response to intravitreal triamcinolone acetonide will be reviewed. RECENT
FINDINGS: Primary open-angle glaucoma, status as a glaucoma suspect, and a family history of glaucoma are risk factors for an ocular hypertensive response with the use of corticosteroid therapy. Recent studies suggest that younger age may also be a risk factor in patients treated via the intravitreal route with corticosteroids. The mechanism of elevated intraocular pressure is increased aqueous outflow resistance owing to an accumulation of extracellular matrix material in the trabecular meshwork.
SUMMARY: Corticosteroid-induced ocular hypertension and glaucoma has been recognized for more than 50 years. Knowing the risk factors, prevalence, and pathophysiology can help the clinician prevent, monitor, and treat corticosteroid-induced ocular hypertension and glaucoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16552251     DOI: 10.1097/01.icu.0000193079.55240.18

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  117 in total

Review 1.  Inflammation in diabetic retinopathy.

Authors:  Johnny Tang; Timothy S Kern
Journal:  Prog Retin Eye Res       Date:  2011-05-25       Impact factor: 21.198

Review 2.  Sustained-release steroids for the treatment of diabetic macular edema.

Authors:  Alejandra Daruich; Alexandre Matet; Francine Behar-Cohen
Journal:  Curr Diab Rep       Date:  2015-11       Impact factor: 4.810

3.  Causes of elevated intraocular pressure following implantation of phakic intraocular lenses for myopia.

Authors:  Salem Almalki; Abdullah Abubaker; Nasser A Alsabaani; Deepak P Edward
Journal:  Int Ophthalmol       Date:  2015-08-12       Impact factor: 2.031

4.  Long-term stability of uveitis with faint anterior chamber flare treated with once-daily topical ophthalmic betamethasone.

Authors:  Masahide Kawamura; Masahiro Zako
Journal:  Inflammation       Date:  2014-04       Impact factor: 4.092

5.  Early and frequent development of ocular hypertension in children with nephrotic syndrome.

Authors:  Emi Kawaguchi; Kenji Ishikura; Riku Hamada; Yoshinobu Nagaoka; Yoshihiko Morikawa; Tomoyuki Sakai; Yuko Hamasaki; Hiroshi Hataya; Eiichiro Noda; Masaru Miura; Takashi Ando; Masataka Honda
Journal:  Pediatr Nephrol       Date:  2014-05-24       Impact factor: 3.714

Review 6.  Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine.

Authors:  M Elizabeth Fini; Stephen G Schwartz; Xiaoyi Gao; Shinwu Jeong; Nitin Patel; Tatsuo Itakura; Marianne O Price; Francis W Price; Rohit Varma; W Daniel Stamer
Journal:  Prog Retin Eye Res       Date:  2016-09-22       Impact factor: 21.198

7.  Triamcinolone acetonide decreases outflow facility in C57BL/6 mouse eyes.

Authors:  Sandeep Kumar; Shaily Shah; Emily Rose Deutsch; Hai Michael Tang; John Danias
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-01       Impact factor: 4.799

8.  Treatment of sheep steroid-induced ocular hypertension with a glucocorticoid-inducible MMP1 gene therapy virus.

Authors:  Rosana Gerometta; Maria-Grazia Spiga; Teresa Borrás; Oscar A Candia
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-20       Impact factor: 4.799

9.  Development of a gene therapy virus with a glucocorticoid-inducible MMP1 for the treatment of steroid glaucoma.

Authors:  Maria-Grazia Spiga; Teresa Borrás
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-20       Impact factor: 4.799

Review 10.  Clinical Applications of Dexamethasone for Aged Eyes.

Authors:  Beatriz Abadia; Pilar Calvo; Antonio Ferreras; Fran Bartol; Guayente Verdes; Luis Pablo
Journal:  Drugs Aging       Date:  2016-09       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.